Enterprise Value
1.276B
Cash
269.5M
Avg Qtr Burn
N/A
Short % of Float
22.27%
Insider Ownership
1.02%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nucynta (tapentadol) Tablets / Extended-Release Tablets Details Pain, Acute pain | Approved Quarterly sales | |
Belbuca (Buprenorphine) Details Chronic pain | Approved Quarterly sales | |
Xtampza ER (oxycodone) Details Pain, Acute pain | Approved Quarterly sales | |
Approved Quarterly sales | ||
Symproic (naldemedine) Details Opioid induced constipation, Bowel preparation | Approved Quarterly sales |